mTOR: Role in cancer, metastasis and drug resistance

Murugan, Avaniyapuram Kannan·2019·Seminars in Cancer Biology
DOI 10.1016/j.semcancer.2019.07.003

Cites (234)

Items 201–228 of 228

  1. Germline activating MTOR mutation arising through gonadal mosaicism in two brothers with megalencephaly and neurodevelopmental abnormalities
    Cameron Mroske, Kristen J. Rasmussen, Deepali N. Shinde, Robert Huether, Zöe Powis, Hsiao‐Mei Lu, Ruth M. Baxter, Elizabeth W. McPherson, Sha Tang · 2015 · BMC Medical Genetics
  2. First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.
    Udai Banerji, Emma Jane Dean, Michael Gonzalez, Alastair Greystoke, Bristi Basu, Matthew Krebs, Martina Puglisi, Lynda M Grinsted, Elisabeth Maria Oelmann, Wendy Burke et al. · 2012 · Journal of Clinical Oncology
  3. Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer
    William J. Gibson, Daniel T. Ruan, Vera Paulson, Justine A. Barletta, Glenn J. Hanna, Stefan Kraft, Antonio Calles, Matthew Alexander Nehs, Francis D. Moore, Amaro N Taylor-Weiner et al. · 2016 · Clinical Cancer Research
  4. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer
    Tetsuo Mashima, Yoko Taneda, Myung-Kyu Jang, Anna Mizutani, Yukiko Muramatsu, Haruka Yoshida, Ayana Sato, Noritaka Tanaka, Yoshikazu Sugimoto, Hiroyuki Seimiya · 2017 · Oncotarget
  5. Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer
    Hiroyuki Yamaguchi, Masahito Kawazu, Takahiko Yasuda, Manabu Soda, Toshihide Ueno, Shinya Kojima, Masakazu Yashiro, Ichiro Yoshino, Yuichi Ishikawa, Eirin Sai et al. · 2015 · Cancer Science
  6. Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression
    Ji Hyun Park, Min‐Hee Ryu, Young Soo Park, Sook Ryun Park, Young-Soon Na, Baek-Yeol Rhoo, Yoon‐Koo Kang · 2015 · BMC Cancer
  7. Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer
    Maria Tsoli, Carol Wadham, Mark Pinese, Timothy W. Failes, Swapna Mahurkar Joshi, Emily V. A. Mould, Julia X. M. Yin, Velimir Gayevskiy, Amit Kumar, Warren H. Kaplan et al. · 2018 · Cancer Biology & Therapy
  8. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant
    Christine A. Parachoniak, Andrew Rankin, Bernadette Gaffney, Ryan James Hartmaier, Dan Spritz, Rachel Erlich, Vincent A. Miller, Deborah Morosini, Phil J. Stephens, Jeffrey S. Ross et al. · 2017 · Molecular Case Studies
  9. Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip
    Annie Y. Chou, Nusi P. Dekker, Richard C. Jordan · 2009 · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
  10. p70S6K1 (S6K1)-mediated Phosphorylation Regulates Phosphatidylinositol 4-Phosphate 5-Kinase Type I γ Degradation and Cell Invasion
    Naser Jafari, Qiaodan Zheng, Liqing Li, Wei Li, Lei Qi, Jianyong Xiao, Tianyan Gao, Cai Huang · 2016 · Journal of Biological Chemistry
  11. Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase
    Wu Tzung-Ju, Xiaowen Wang, Yanjie Zhang, Linghua Meng, John E. Kerrigan, Stephen Kevin Burley, X.F. Steven Zheng · 2015 · Cell Reports
  12. Involvement of mTOR signaling pathways in regulating growth and dissemination of metastatic brain tumors via EMT.
    Amanda M. Kwasnicki, Dhruve S. Jeevan, Alex Braun, Raj Murali, Meena Jhanwar‐Uniyal · 2015 · PubMed
  13. Genomic profiling of esophageal squamous cell carcinoma (ESCC)—Basis for precision medicine
    Jung Wook Yang, Yoon‐La Choi · 2017 · Pathology - Research and Practice
  14. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR -Activating Mutation
    Juan Francisco Rodríguez-Moreno, María Apellániz-Ruiz, Juan María Roldán‐Romero, Ignacio Durán, Luis Beltrán, Cristina Montero‐Conde, Alberto Cascón, Mercedes Robledo, Jesús García-Donás, Cristina Rodríguez‐Antona · 2017 · Journal of the National Comprehensive Cancer Network
  15. Smith–Kingsmore syndrome: A third family with the MTOR mutation c.5395G>A p.(Glu1799Lys) and evidence for paternal gonadal mosaicism
    Shahida Moosa, Helena Böhrer‐Rabel, Janine Altmüller, Filippo Beleggia, Peter Nürnberg, Yun Li, Gökhan Yigit, Bernd Wollnik · 2016 · American Journal of Medical Genetics Part A
  16. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer
    Muslim L. Alabdullah, Dena A. J. Ahmad, Paul M. Moseley, Srinivasan Madhusudan, Stephen Y.T. Chan, Emad A. Rakha · 2019 · Journal of Obstetrics and Gynaecology
  17. mTOR Is Key to T Cell Transdifferentiation
    Jiawei Yan, Ruoning Wang, Tiffany Horng · 2019 · Cell Metabolism
  18. Absence of somatic mutations of the mTOR gene in differentiated thyroid cancer
    Avaniyapuram Kannan Murugan, Eman A. Humudh, Ebtesam Qasem, Hindi Al‐Hindi, Mai Almohanna, Zeinab Korany Hassan, Ali Saeed Alzahrani · 2015 · Meta Gene
  19. Preclinical validation of a novel compound targeting p70S6 kinase in breast cancer
    Ilenia Segatto, Samuele Massarut, Robert J. Boyle, Gustavo Baldassarre, David Walker, Barbara Belletti · 2016 · Aging
  20. Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway
    Weiqing Wang, H Chen, Zebing Liu, P Qu, Jianyun Lan, H Chen, L Zou, Jianxin Qiu · 2016 · British Journal of Cancer
  21. Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?
    Michael S. Lee, Bert H. O’Neil · 2016 · Journal of Gastrointestinal Oncology
  22. Meta-analysis of the prognostic value of p-4EBP1 in human malignancies
    Tao Zhang, Jianrong Guo, Huili Li, Jiliang Wang · 2017 · Oncotarget
  23. Levels of 4EBP1/eIF4E Activation in Renal Cell Carcinoma Could Differentially Predict Its Early and Late Recurrence
    Osamu Ichiyanagi, Sei Naito, Hiromi Ito, Takanobu Kabasawa, Takafumi Narisawa, Hidenori Kanno, Yuta Kurota, Masayuki Kurokawa, Hiroki Fukuhara, Toshihiko Sakurai et al. · 2018 · Clinical Genitourinary Cancer
  24. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells
    Maochuan Zhen, Fuqiang Wang, Shaofeng Wu, Yilin Zhao, Ping‐Guo Liu, Zhenyu Yin · 2016 · Oncotarget
  25. Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine
    Erika Parasido, Alessandra Silvestri, Vincenzo Canzonieri, Claudio Belluco, Maria Grazia Diodoro, Massimo Milione, Flavia Melotti, Ruggero D. Maria, Lance A. Liotta, Emanuel F. Petricoin et al. · 2016 · Oncotarget
  26. Phase I Trial of Everolimus and Capecitabine in Metastatic HER2− Breast Cancer
    Gregory A. Vidal, Mary M. Chen, Shruti Sheth, Tiffany H. Svahn, Ellie Guardino · 2017 · Clinical Breast Cancer
  27. Downregulation of mTOR and P70S6Kβ2 in Pediatric T-Cell Acute Lymphoblastic Leukemia (T-ALL) Is Correlated with a Poor Prognosis
    Paola Bonaccorso, Manuela Tumino, Angela D’Ambra, Elena Mirabile, Martina Barchitta, Amelia Poli, Daria Bottino, Manuela La Rosa, Antonella Agodi, Luca Lo Nigro · 2011 · Blood
  28. Photoaffinity labelling of the human platelet thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor.
    Mais De, Perry V. Halushka · 1989 · PubMed